News Conference News ACC 2024 ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI Yael L. Maxwell April 07, 2024
News Conference News ACC 2023 CRP More Predictive of Future Events Than LDL in Statin-Treated Patients Caitlin E. Cox March 14, 2023
News Conference News ACC 2023 Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA Yael L. Maxwell March 09, 2023
News Conference News ACC 2022 Managing AF Patients Undergoing PCI—Some Lingering Questions Michael O'Riordan April 12, 2022
News Conference News ACC 2021 Clopidogrel, Not Aspirin, for Post-DAPT Monotherapy After PCI: HOST-EXAM L.A. McKeown May 16, 2021
News Conference News ACC 2019 Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY Yael L. Maxwell March 27, 2019
News Conference News ACC 2019 Dropping Aspirin: Two Trials Explore P2Y12 Monotherapy After Short-term DAPT Post-PCI Yael L. Maxwell March 18, 2019
News Conference News ACC 2018 Genetic Testing Influences Post-PCI Antiplatelet Prescriptions, but Other Factors Also Play a Role Yael L. Maxwell March 11, 2018
News Conference News ACC 2018 Reducing Co-payments for P2Y12 Inhibitors Upped Ticagrelor Use but Didn’t Budge MACE: ARTEMIS Caitlin E. Cox March 11, 2018
News Conference News ACC 2018 ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last Shelley Wood March 05, 2018
News Conference News ACC 2017 Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe Todd Neale March 18, 2017
News Conference News ACC 2016 Meta-analysis Delves Into Bivalirudin Versus Heparin Debate in Primary PCI Yael L. Maxwell April 04, 2016
News Conference News ACC 2014 EUROMAX: Bivalirudin May Hold Key to Solving Problem of Early ST After Primary PCI Jason Kahn March 29, 2014